TABLE 3. Clinical efficacy of goserelin plus tamoxifen versus goserelin alone in 318 premenopausal patients with advanced breast cancer *

Randomized Treatment


Goserelin
alone
(n=159)

Goserelin plus Tamoxifen (n=159)




p value

Objective response (CR + PR), n(%)

50 (31)

60 (38)

0.24

complete response

8 (5)

12 (8)

partial response

42 (26)

48 (30)

No change, n (%)

51 (32)

42 (26)

Progression, n (%)

49 (31)

47 (30)

Median duration of response, weeks (range)

59 (12-216)

88 (8-196)

Median time to first progression, weeks (range)

23 (0-216)

28 (0-196)

0.03

Median survival, weeks (range)

127 (0-303)

140 (0-298)

0.25

CR, complete response; PR, Partial response
(From ref. 44, reproduced with permission of Elsevier Science Ltd).
Back to Chapter

 

 

published 2000